UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/572,343	03/17/2006	Richard Isaacs	21367YP 7502	
MERCK AND	7590 06/11/200 CO., INC	EXAMINER		
P O BOX 2000			DAVIS, ZINNA NORTHINGTON	
RAHWAY, NJ 07065-0907			ART UNIT	PAPER NUMBER
			1625	
			MAIL DATE	DELIVERY MODE
			06/11/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/572,343	ISAACS ET AL.			
Office Action Summary	Examiner	Art Unit			
	Zinna Northington Davis	1625			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) ☐ Responsive to communication(s) filed on 27 M. 2a) ☐ This action is FINAL . 2b) ☐ This 3) ☐ Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) Claim(s) 1-23 is/are pending in the application. 4a) Of the above claim(s) 8-18 and 21-23 is/are 5) Claim(s) is/are allowed. 6) Claim(s) 1-6,19 and 20 is/are rejected. 7) Claim(s) 7 is/are objected to. 8) Claim(s) are subject to restriction and/or Application Papers 9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the or	e withdrawn from consideration. r election requirement. r. epted or b) □ objected to by the B				
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119	ammer. Note the attached office	7. CHOT OF TOTHER 102.			
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some color None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 06/12/06.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	nte			

Art Unit: 1625

DETAILED ACTION

- 1. Claims 1-23 are pending.
- 2. In the response filed March 27, 2009, Applicants have elected Group I, claims 1-7, 19 and 20, without traverse. Applicants also identify the compound of Formula I wherein A is 3-fluorophenyl, R¹ is H, R² is H, R⁵ is –C(O)OR⁵⁵, R⁵⁵ is H, R⁸ is H, R⁹ is OR⁴³, wherein R⁴³ is C1-C6 alkyl and R¹⁰ is H as the preferred species.
- 3. Claims 8-18 and 21-23 are withdrawn from consideration.
- 4. Rejoinder of the method claims will be addressed upon allowance of claimed subject matter.
- 5. Applicants are reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).
- 6. Claims 1-7, 19, and 20 are Markush claims which are generic to the elected invention. These Markush claims lack unity of invention. Accordingly, the Markush type claim will be examined fully with respect to the elected species and further to the extent necessary to determine patentability. See MPEP 803.02.
- 7. Claims 1-7, 19, and 20 are objected on the grounds that the claims are drawn to an improper Markush group. <u>In re Harnisch</u>, 206 USPQ 300, states that a unity of invention exists where compounds included within a Markush group(1) share a common

Art Unit: 1625

utility and (2) share a substantial structural feature disclosed as being essential to that utility. In the instant case, the claimed subject matter does not share a substantial structural feature disclosed as being essential to that utility.

- 8. The requirement for a proper Markush claim is that it includes only substances that in their physical, chemical and physiological characteristics are functionally equivalent. The members of the instant Markush groups possess widely different, physical and chemical properties. The compounds are not considered functionally equivalent and are so diverse that they demonstrate dissimilar and unrelated properties. The mere fact that there is structural similarity in pharmaceutical agents is not in itself reason to render all the embodiments functionally equivalent.
- 9. The improper Markush groups are A, R⁵, R², R⁸, R⁹, and R¹⁰.
- 10. The examined subject matter is as follows:

A compound of formula I wherein A is aryl; R⁵ is -C(O)OR⁵⁵; and one of R², R⁸, R⁹, and R¹⁰ is -OR⁴³. The radicals not defined herein are defined according to claim 1. Amending the claims to the examined subject matter would overcome the improper Markush rejection.

11. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

- (b) The invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 12. Claims 1-6, 19, and 20 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Takeda Chemical Industries, Ltd. (Reference N, cited by the Examiner).

Art Unit: 1625

The instantly claimed compounds are disclosed. At page 83, see formula II-b.

For instance, at page 360, see lines 18-19. The compounds are depicted below:

Art Unit: 1625

13. Claim 7 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

and

- 14. The Information Disclosure Statement filed June 12, 2006 has been considered.
- 15. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zinna Northington Davis whose telephone number is 571-272-0682.
- 16. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300 for regular communications.
- 17. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

Art Unit: 1625

you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

_/Zinna Northington Davis/ Zinna Northington Davis Primary Examiner Art Unit 1625

Znd 06.08.2009